The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored. Click here for full details.